Volume 39, Issue 3 pp. 363-369
Clinical Science
Full Access

The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus

Dafna Gladman MD, FRCPC

Corresponding Author

Dafna Gladman MD, FRCPC

ACR Diagnostic and Therapeutic Criteria Committee Liaison to SLICC, The Toronto Hospital, Toronto, Ontario, Canada

Address reprint requests to American College of Rheumatology, 60 Executive Park South, Suite 150, Atlanta, GA 30329Search for more papers by this author
Ellen Ginzler MD, MPH

Ellen Ginzler MD, MPH

State University of New York Health Science Center at Brooklyn

Search for more papers by this author
Charles Goldsmith PhD

Charles Goldsmith PhD

McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
Paul Fortin MD, MPH

Paul Fortin MD, MPH

Montreal General Hospital, Montreal, Quebec, Canada

Search for more papers by this author
Matthew Liang MD, MPH

Matthew Liang MD, MPH

Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts

Search for more papers by this author
Jorge Sanchez-Guerrero MD

Jorge Sanchez-Guerrero MD

Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts

Search for more papers by this author
Murray Urowitz MD, FRCPC

Murray Urowitz MD, FRCPC

The Toronto Hospital, Toronto

Search for more papers by this author
Paul Bacon MD, FRCP

Paul Bacon MD, FRCP

Birmingham University, Birmingham, England

Search for more papers by this author
Stefano Bombardieri MD

Stefano Bombardieri MD

University of Pisa, Pisa, Italy

Search for more papers by this author
John Hanly MD, FRCPC

John Hanly MD, FRCPC

Dalhousie University, Halifax, Nova Scotia, Canada

Search for more papers by this author
John Jones MD, FRCPC

John Jones MD, FRCPC

Dalhousie University, Halifax, Nova Scotia, Canada

Search for more papers by this author
Elaine Hay MD

Elaine Hay MD

University of Manchester, Manchester, England

Search for more papers by this author
Deborah Symmons MD, MRCP

Deborah Symmons MD, MRCP

University of Manchester, Manchester, England

Search for more papers by this author
David Isenberg MD, MRCP

David Isenberg MD, MRCP

University College and Middlesex Hospital Medical School, London, England

Search for more papers by this author
Kenneth Kalunion MD

Kenneth Kalunion MD

University of California, Los Angeles

Search for more papers by this author
Peter Maddison MD

Peter Maddison MD

Royal National Hospital for The Rheumatic Diseases, Bath, England

Search for more papers by this author
Ola Nived MD, PhD

Ola Nived MD, PhD

University Hospital, Lund, Sweden

Search for more papers by this author
Gunnar Sturfelt MD

Gunnar Sturfelt MD

University Hospital, Lund, Sweden

Search for more papers by this author
Michelle Petri MD, MPH

Michelle Petri MD, MPH

Johns Hopkins Medical School, Baltimore, Maryland

Search for more papers by this author
Martin Richter PhD

Martin Richter PhD

St. Vincent Hospital, Darlinghurst, Sydney, New South Wales, Australia

Search for more papers by this author
Michael Snaith MD, FRCP

Michael Snaith MD, FRCP

Hallamshire Hospital, Sheffield, England

Search for more papers by this author
Asad Zoma MD

Asad Zoma MD

Stonehouse Hospital, Stonehouse, Scotland

Search for more papers by this author
First published: March 1996
Citations: 2,043

Abstract

Objective. To develop and perform an initial validation of a damage index for systemic lupus erythematosus (SLE).

Methods. A list of items considered to reflect damage in SLE was generated through a nominal group process. A consensus as to which items to be included in an index was reached, together with rules for ascertainment. Each center submitted 2 assessments, 5 years apart, on 2 patients with active and 2 with inactive disease, of whom 1 had increased damage and the other had stable disease. Analysis of variance was used to test the factors physician, time, amount of damage, and activity status.

Results. Nineteen physicians completed the damage index on 42 case scenarios. The analysis revealed that the damage index could identify changes in damage seen in patients with both active and inactive disease. Patients who had active disease at both time points had a higher increase in damage. There was good agreement among the physicians on the assessment of damage in these patients.

Conclusion. This damage index for SLE records damage occurring in patients with SLE regardless of its cause. The index was demonstrated to have content, face, criterion, and discriminant validity.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me